Key Points
- Director Stan Smith purchased 57,189 shares of MAIA on December 22 at an average price of $1.22 (total $69,770.58), bringing his ownership to 1,421,478 shares, a 4.19% increase.
- MAIA shares opened at $1.36 with a market cap of $50.36 million; the stock has a 50‑day moving average of $1.21, 200‑day average of $1.50, a one‑year range of $0.87–$2.74, and a negative P/E after reporting ($0.27) EPS, missing estimates.
- MAIA Biotechnology is a clinical‑stage biopharma developing site‑specific antibody–radioisotope conjugates for PET imaging and targeted radiotherapeutics.
MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Get Free Report) Director Steven Chaouki purchased 40,849 shares of the firm's stock in a transaction on Monday, December 22nd. The shares were acquired at an average cost of $1.22 per share, for a total transaction of $49,835.78. Following the completion of the acquisition, the director owned 151,873 shares of the company's stock, valued at approximately $185,285.06. This trade represents a 36.79% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
MAIA Biotechnology Stock Up 2.3%
MAIA opened at $1.36 on Wednesday. The firm has a 50-day simple moving average of $1.21 and a two-hundred day simple moving average of $1.50. MAIA Biotechnology, Inc. has a 52 week low of $0.87 and a 52 week high of $2.74. The company has a market capitalization of $50.36 million and a PE ratio of -1.86.
MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) last issued its quarterly earnings data on Friday, November 7th. The company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.08). As a group, sell-side analysts expect that MAIA Biotechnology, Inc. will post -1.3 earnings per share for the current year.
Hedge Funds Weigh In On MAIA Biotechnology
A number of institutional investors have recently modified their holdings of the stock. Centerpoint Advisory Group purchased a new stake in shares of MAIA Biotechnology in the 2nd quarter worth approximately $28,000. Marshall Wace LLP purchased a new stake in MAIA Biotechnology in the second quarter valued at about $29,000. Jane Street Group LLC purchased a new stake in MAIA Biotechnology during the 2nd quarter worth approximately $52,000. Geode Capital Management LLC increased its position in shares of MAIA Biotechnology by 3.6% in the 2nd quarter. Geode Capital Management LLC now owns 222,183 shares of the company's stock valued at $400,000 after acquiring an additional 7,746 shares during the period. Finally, Centric Wealth Management raised its stake in shares of MAIA Biotechnology by 740.2% in the second quarter. Centric Wealth Management now owns 573,398 shares of the company's stock worth $1,032,000 after purchasing an additional 505,150 shares during the last quarter. 5.65% of the stock is owned by hedge funds and other institutional investors.
About MAIA Biotechnology
(
Get Free Report)
MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.
The company's pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
